These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 36140121)
21. From discovery to the clinic: the novel DNA methylation biomarker (m)SEPT9 for the detection of colorectal cancer in blood. Payne SR Epigenomics; 2010 Aug; 2(4):575-85. PubMed ID: 22121975 [TBL] [Abstract][Full Text] [Related]
22. Methylated septin 9 gene is an important prognostic marker in stage II and stage III colorectal cancer for evaluating local recurrence or distant metastasis after surgery. Huang M; He J; Lai W; Liu L; Xu H; Zeng Y; Lan Q; Lin X; Chu Z BMC Gastroenterol; 2022 Feb; 22(1):87. PubMed ID: 35227194 [TBL] [Abstract][Full Text] [Related]
23. SEPT9: A Specific Circulating Biomarker for Colorectal Cancer. Song L; Li Y Adv Clin Chem; 2015; 72():171-204. PubMed ID: 26471083 [TBL] [Abstract][Full Text] [Related]
24. Distinct Performance of Methylated Tang H; Ma X; Zhou L; Li W; Shu Y; Xu H; Li J; Wang F; Sun F; Duan Y Genet Test Mol Biomarkers; 2022 Apr; 26(4):239-248. PubMed ID: 35481971 [No Abstract] [Full Text] [Related]
25. Electrochemical DNA Biosensing via Electrochemically Controlled Reversible Addition-Fragmentation Chain Transfer Polymerization. Hu Q; Kong J; Han D; Niu L; Zhang X ACS Sens; 2019 Jan; 4(1):235-241. PubMed ID: 30620562 [TBL] [Abstract][Full Text] [Related]
26. The quantitative profiling of blood mSEPT9 determines the detection performance on colorectal tumors. Song L; Wang J; Wang H; Chen Y; Jia J; Guo S; Liu H; Peng X; Xiao W; Gong Y; Yang B; Lu Y; Li Y Epigenomics; 2018 Dec; 10(12):1569-1583. PubMed ID: 30426784 [TBL] [Abstract][Full Text] [Related]
27. A systematic review of the performance of the SEPT9 gene methylation assay in colorectal cancer screening, monitoring, diagnosis and prognosis. Song L; Yu H; Jia J; Li Y Cancer Biomark; 2017; 18(4):425-432. PubMed ID: 28128742 [TBL] [Abstract][Full Text] [Related]
28. Methylated Septin 9 and Carcinoembryonic Antigen for Serological Diagnosis and Monitoring of Patients with Colorectal Cancer After Surgery. Ma ZY; Law WL; Ng EKO; Chan CSY; Lau KS; Cheng YY; Shin VY; Kwong A; Leung WK Sci Rep; 2019 Jul; 9(1):10326. PubMed ID: 31316143 [TBL] [Abstract][Full Text] [Related]
30. A two-gene blood test for methylated DNA sensitive for colorectal cancer. Pedersen SK; Baker RT; McEvoy A; Murray DH; Thomas M; Molloy PL; Mitchell S; Lockett T; Young GP; LaPointe LC PLoS One; 2015; 10(4):e0125041. PubMed ID: 25928810 [TBL] [Abstract][Full Text] [Related]
31. Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer. Church TR; Wandell M; Lofton-Day C; Mongin SJ; Burger M; Payne SR; Castaños-Vélez E; Blumenstein BA; Rösch T; Osborn N; Snover D; Day RW; Ransohoff DF; Gut; 2014 Feb; 63(2):317-25. PubMed ID: 23408352 [TBL] [Abstract][Full Text] [Related]
32. [Significance of Septin9 gene methylation detection of plasma circulation DNA in colorectal cancer screening]. Kang Q; Jin P; Yang L; Wang X; An H; Liu L; Li N; Sheng J Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(48):3839-41. PubMed ID: 25623318 [TBL] [Abstract][Full Text] [Related]
33. Circulating epigenetic biomarkers for detection of recurrent colorectal cancer. Symonds EL; Pedersen SK; Murray D; Byrne SE; Roy A; Karapetis C; Hollington P; Rabbitt P; Jones FS; LaPointe L; Segelov E; Young GP Cancer; 2020 Apr; 126(7):1460-1469. PubMed ID: 31909823 [TBL] [Abstract][Full Text] [Related]
34. Potential of quantitative SEPT9 and SHOX2 methylation in plasmatic circulating cell-free DNA as auxiliary staging parameter in colorectal cancer: a prospective observational cohort study. Bergheim J; Semaan A; Gevensleben H; Groening S; Knoblich A; Dietrich J; Weber J; Kalff JC; Bootz F; Kristiansen G; Dietrich D Br J Cancer; 2018 May; 118(9):1217-1228. PubMed ID: 29610456 [TBL] [Abstract][Full Text] [Related]
35. Simultaneous Analysis of SEPT9 Promoter Methylation Status, Micronuclei Frequency, and Folate-Related Gene Polymorphisms: The Potential for a Novel Blood-Based Colorectal Cancer Biomarker. Ravegnini G; Zolezzi Moraga JM; Maffei F; Musti M; Zenesini C; Simeon V; Sammarini G; Festi D; Hrelia P; Angelini S Int J Mol Sci; 2015 Dec; 16(12):28486-97. PubMed ID: 26633373 [TBL] [Abstract][Full Text] [Related]
36. The performance of the mSEPT9 assay is influenced by algorithm, cancer stage and age, but not sex and cancer location. Song L; Jia J; Yu H; Peng X; Xiao W; Gong Y; Zhou G; Han X; Li Y J Cancer Res Clin Oncol; 2017 Jun; 143(6):1093-1101. PubMed ID: 28224298 [TBL] [Abstract][Full Text] [Related]
37. Performance of the colorectal cancer screening marker Sept9 is influenced by age, diabetes and arthritis: a nested case-control study. Ørntoft MB; Nielsen HJ; Ørntoft TF; Andersen CL; BMC Cancer; 2015 Oct; 15():819. PubMed ID: 26514170 [TBL] [Abstract][Full Text] [Related]
38. A novel method for early detection of colorectal cancer based on detection of methylation of two fragments of syndecan-2 (SDC2) in stool DNA. Ma L; Qin G; Gai F; Jiang Y; Huang Z; Yang H; Yao S; Du S; Cao Y BMC Gastroenterol; 2022 Apr; 22(1):191. PubMed ID: 35436855 [TBL] [Abstract][Full Text] [Related]
39. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis - an update. Molnár B; Galamb O; Kalmár A; Barták BK; Nagy ZB; Tóth K; Tulassay Z; Igaz P; Dank M Expert Rev Mol Diagn; 2019 Jun; 19(6):477-498. PubMed ID: 31046485 [No Abstract] [Full Text] [Related]
40. Methylation of FBN1, SPG20, ITF2, RUNX3, SNCA, MLH1, and SEPT9 genes in circulating cell-free DNA as biomarkers of colorectal cancer. Alizadeh-Sedigh M; Fazeli MS; Mahmoodzadeh H; Sharif SB; Teimoori-Toolabi L Cancer Biomark; 2022; 34(2):221-250. PubMed ID: 34957998 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]